Kristen Ambrose is CAO & VP at VERTEX PHARMACEUTICALS INC / MA (VRTX). They have made 2 open-market trades across 1 company since 2022, most recently 2026-08-28.
CIK 0001856587
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| VRTX | 11,624 | $5.8M |
Shares reported on the most recent Form 4, priced at the 2026-09-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VRTX | SELL · 10b5-1 | 2026-02-26 | 2026-03-02 | $483.36 | $173K | -0.2% | -6.6% | -8.5% |
| VRTX | SELL · 10b5-1 | 2026-02-25 | 2026-02-26 | $486.35 | $108K | +3.9% | -7.7% | -9.0% |
| VRTX | SELL | 2026-02-17 | 2026-02-19 | $484.87 | $1.1M | +1.6% | -3.4% | -7.9% |
| VRTX | SELL · 10b5-1 | 2026-02-11 | 2026-02-12 | $460.43 | $634K | +2.4% | -1.2% | -3.9% |
| VRTX | SELL · 10b5-1 | 2025-02-25 | 2025-02-26 | $480.95 | $850K | +5.2% | +3.6% | -6.2% |
| VRTX | SELL · 10b5-1 | 2025-02-18 | 2025-02-19 | $455.06 | $611K | +2.0% | +6.2% | -5.7% |
| VRTX | SELL · 10b5-1 | 2025-02-11 | 2025-02-12 | $459.83 | $1.3M | +5.7% | +11.1% | -4.9% |
| VRTX | SELL · 10b5-1 | 2024-04-02 | 2024-04-03 | $419.00 | $101K | -3.7% | -2.8% | +14.8% |
| VRTX | SELL · 10b5-1 | 2024-02-26 | 2024-02-27 | $425.70 | $752K | -3.7% | -2.7% | +4.0% |
| VRTX | SELL · 10b5-1 | 2024-02-12 | 2024-02-13 | $420.24 | $1.2M | +3.6% | -2.3% | +2.8% |
| VRTX | SELL · 10b5-1 | 2023-05-30 | 2023-06-01 | $329.82 | $191K | +5.9% | +7.6% | +8.6% |
| VRTX | SELL | 2023-02-27 | 2023-02-28 | $287.51 | $682K | -0.6% | +8.0% | +12.5% |
| VRTX | SELL · 10b5-1 | 2022-04-25 | 2022-04-27 | $269.55 | $88K | -12.5% | +1.9% | +7.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.